RenovoRx (RNXT) CFO’s family trust buys stock and warrants in $100K deal
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
RenovoRx, Inc. Chief Financial Officer Mark Voll, through the Voll Family Trust, reported buying both common stock and warrants in a private placement. The trust acquired 97,200 shares of common stock and 48,600 warrants, for an aggregate purchase price of $100,000.
The warrants are exercisable immediately at $1.9326 per share of underlying common stock and will expire on the earlier of March 30, 2029 or 30 days after RenovoRx reports at least $1.5 million in product sales revenue for any calendar quarter.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Net Buy
2 txns
Insider
VOLL MARK
Role
Chief Financial Officer
Bought
145,800 shs ($0.00)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Warrants | 48,600 | $0.00 | -- |
| Purchase | Common Stock | 97,200 | $0.00 | -- |
Holdings After Transaction:
Warrants — 48,600 shares (Indirect, Voll Family Trust DTD 6/23/2010 Mark Voll TTEE);
Common Stock — 97,200 shares (Indirect, Voll Family Trust DTD 6/23/2010 Mark Voll TTEE)
Footnotes (1)
- The securities were purchased in a private placement on March 20, 2026 for an aggregate of $100,000. The warrants are exercisable immediately upon issuance and expire on the earlier of (i) March 30, 2029 or (ii) 30 days following the date the Issuer reports at least $1.5 million in product sales revenue (excluding licensing fees, upfront milestones and grants, but including royalty revenue from product sales) for any calendar quarter in a quarterly or annual report.
FAQ
What insider transactions did RenovoRx (RNXT) report for CFO Mark Voll?
RenovoRx reported that CFO Mark Voll, via the Voll Family Trust, bought warrants and common stock. The trust acquired 48,600 warrants and 97,200 common shares in a private placement, reflecting an indirect increase in his economic exposure to RenovoRx.
What was the total dollar amount of the RenovoRx (RNXT) insider purchase?
The securities were purchased for an aggregate of $100,000. This total covers both the common stock and the warrants acquired in the private placement completed on March 20, 2026, as disclosed in the filing footnotes.
What are the exercise terms of the RenovoRx (RNXT) warrants bought by the Voll Family Trust?
The warrants are exercisable immediately at an exercise price of $1.9326 per share. They expire on March 30, 2029, or 30 days after RenovoRx reports at least $1.5 million in product sales revenue for any calendar quarter.
How are the RenovoRx (RNXT) securities owned by CFO Mark Voll held?
The reported common stock and warrants are held indirectly through the Voll Family Trust. The filing lists ownership as indirect, with the nature of ownership described as “Voll Family Trust DTD 6/23/2010 Mark Voll TTEE” for both securities.
Does the RenovoRx (RNXT) Form 4 show buying or selling by the CFO’s trust?
The Form 4 shows net buying activity by the Voll Family Trust. Two purchase transactions were reported, with a combined 145,800 securities across common stock and warrants, and no sales or dispositions recorded in this filing.